SERPINE1 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant SERPINE1.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IP, E |
---|---|
Primary Accession | P05121 |
Other Accession | NM_000602 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 3F2 |
Calculated MW | 45060 Da |
Gene ID | 5054 |
---|---|
Other Names | Plasminogen activator inhibitor 1, PAI, PAI-1, Endothelial plasminogen activator inhibitor, Serpin E1, SERPINE1, PAI1, PLANH1 |
Target/Specificity | SERPINE1 (NP_000593, 86 a.a. ~ 185 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | SERPINE1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
References
1.Extracellular Matrix Remodeling by Bone Marrow Fibroblast-like Cells Correlates with Disease Progression in Multiple Myeloma.Slany A, Haudek-Prinz V, Meshcheryakova A, Bileck A, Lamm W, Zielinski C, Gerner C, Drach JJ Proteome Res. 2013 Dec 2.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.